These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 27458623)

  • 21. New therapeutic options in rheumatoid arthritis: a focus on interleukin-6 blockade.
    Furfaro N
    J Infus Nurs; 2011; 34(2):107-15. PubMed ID: 21399456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The role of interleukin-6 in rheumatoid arthritis].
    Manfredi M; Benucci M
    Recenti Prog Med; 2008 Jun; 99(6):291-4. PubMed ID: 18710059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage.
    Prescrire Int; 2009 Oct; 18(103):198-201. PubMed ID: 19882783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)].
    Nasonov EL
    Ter Arkh; 2010; 82(5):64-71. PubMed ID: 20597275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
    Sagawa A
    Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-6 inhibition and clinical efficacy in rheumatoid arthritis treatment--data from randomized clinical trials.
    Kavanaugh A
    Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S16-20. PubMed ID: 17708740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Tocilizumab in rheumatoid arthritis. Interleukin 6 as a new target].
    Heinzl S
    Med Monatsschr Pharm; 2008 Dec; 31(12):450-3. PubMed ID: 19133593
    [No Abstract]   [Full Text] [Related]  

  • 28. Biologic agents for rheumatoid arthritis: 2008 and beyond.
    Sweiss NJ; Hushaw LL
    J Infus Nurs; 2009; 32(1 Suppl):S4-17; quiz S19-24. PubMed ID: 19142153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical effects of tocilizumab on cytokines and immunological factors in patients with rheumatoid arthritis.
    Kasama T; Isozaki T; Takahashi R; Miwa Y
    Int Immunopharmacol; 2016 Jun; 35():301-306. PubMed ID: 27085681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned?
    Avci AB; Feist E; Burmester GR
    BioDrugs; 2024 Jan; 38(1):61-71. PubMed ID: 37989892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical safety of tocilizumab in rheumatoid arthritis.
    Bannwarth B; Richez C
    Expert Opin Drug Saf; 2011 Jan; 10(1):123-31. PubMed ID: 21121872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis.
    Zhang X; Peck R
    Expert Rev Clin Pharmacol; 2011 Sep; 4(5):539-58. PubMed ID: 22114882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Humanized anti-human IL-6 receptor antibody, tocilizumab].
    Nishimoto N
    Nihon Rinsho; 2007 Jul; 65(7):1218-25. PubMed ID: 17642235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tocilizumab-induced psoriasiform rash in rheumatoid arthritis.
    Palmou-Fontana N; Sánchez Gaviño JA; McGonagle D; García-Martinez E; Iñiguez de Onzoño Martín L
    Dermatology; 2014; 228(4):311-3. PubMed ID: 24942661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab.
    Nishimoto N; Hashimoto J; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Murata N; van der Heijde D; Kishimoto T
    Ann Rheum Dis; 2007 Sep; 66(9):1162-7. PubMed ID: 17485422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Humanized antihuman IL-6 receptor antibody, tocilizumab.
    Nishimoto N; Kishimoto T
    Handb Exp Pharmacol; 2008; (181):151-60. PubMed ID: 18071945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Lipid profile and cardiovascular risk in patients with rheumatoid arthritis: Effect of the disease and of drug therapy].
    Hansel B; Bruckert E
    Ann Endocrinol (Paris); 2010 Sep; 71(4):257-63. PubMed ID: 20416859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical benefits of anti-human IL-6 receptor antibody therapy].
    Nishimoto N
    Clin Calcium; 2007 Apr; 17(4):562-8. PubMed ID: 17404486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.
    Hugh J; Van Voorhees AS; Nijhawan RI; Bagel J; Lebwohl M; Blauvelt A; Hsu S; Weinberg JM
    J Am Acad Dermatol; 2014 Jan; 70(1):168-77. PubMed ID: 24184141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polyarticular late infection of total joint arthroplasties in a patient with rheumatoid arthritis treated with anti-interleukin-6 therapy.
    Wakabayashi H; Takigawa S; Hasegawa M; Kakimoto T; Yoshida K; Sudo A
    Rheumatology (Oxford); 2014 Jun; 53(6):1150-1. PubMed ID: 24273024
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.